Anamorelin Study Correction Published in Cachexia Journal

On August 1, 2026, the Journal of Cachexia, Sarcopenia and Muscle published a correction related to anamorelin research. The correction pertains to the article titled "A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)." This original study examined anamorelin use during chemoimmunotherapy in patients with non-small cell lung cancer who had cachexia. The newly published item is specifically identified as a correction to that prior publication. No details of the correction's content, such as which sections or data points were amended, were included in the event information provided. Anamorelin remains classified as an unapproved compound under research status. This publication update was indexed under PubMed ID 42552565. Readers interested in the underlying study details should consult the original SPIRAL-ANA article alongside this correction for full context. As with any correction notice, it reflects an editorial update to previously published material rather than new findings or new data on anamorelin's effects. No efficacy or safety conclusions can be drawn from this correction notice alone. For more background on anamorelin, readers can refer to the compound overview.